Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Adults With House Dust Mite-associated Asthma
NCT05720325Phase 2Active, not recruiting
- Sponsor
- UT Health San Antonio
- Start
- Mar 2023
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of dupilumab in allergic asthma (4 arms), sponsored by UT Health San Antonio. Primary endpoint: Overall change in ACC HDM exposure-induced nasal airway gene expression profile at 18 weeks. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
allergic asthma
Beyond the preview
Go deeper on NCT05720325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720325.